Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2006
From adjuvant to preventive breast cancer treatment: bridging the gap over troubled watersE Ricevuto, Z C Di Rocco, T Sidoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 2004
Reducing breast cancer incidence in familial breast cancer: overlooking the present panoramaP Marchetti, C Z Di Rocco, E Ricevuto, et al.
British Journal of Cancer|May 29, 2003
Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicityG Cianci, M F Morelli, K Cannita, et al.
Journal of Environmental Radioactivity|February 7, 2018
AMS assessment of U-contamination of structural materials of the Garigliano NPP under decommissioningF Terrasi, R Buompane, A D'Onofrio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
Prognostic value of p53 molecular status in high-risk primary breast cancerP Marchetti, K Cannita, E Ricevuto, et al.
Oncology Reports|December 7, 2002
P16 hypermethylation contributes to the characterization of gene inactivation profiles in primary gastric cancerCorrado Ficorella, Katia Cannita, Enrico Ricevuto, et al.
British Journal of Cancer|August 5, 2004
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding studyC Ficorella, M F Morelli, E Ricevuto, et al.
Oncology Reports|April 6, 2006
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding studyC Ficorella, E Ricevuto, M F Morelli, et al.
Tumori|August 9, 2003
[Can analysis of the molecular status of the p53 gene contribute to improving the therapeutic strategy for breast carcinoma?]E Ricevuto, P Marchetti, K Cannita, et al.
Oncology Reports|April 30, 2010
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II studyM F Morelli, A Santomaggio, E Ricevuto, et al.
Pageof 4